Alexandra Miller
Memorial Sloan Kettering Cancer Center
42 Papers
25 Citations
Alexandra Miller is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 5, co-authored 19 publications. Previous affiliations of Alexandra Miller include Cornell University.
Chat about Author
Papers
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
Dan Rohle,Janeta Popovici-Muller,Nicolaos Palaskas,Sevin Turcan,Christian Grommes,Carl Campos,Jennifer Tsoi,Owen Clark,Barbara Oldrini,Evangelia Komisopoulou,Kaiko Kunii,Alicia Pedraza,Stefanie Schalm,Lee Silverman,Alexandra Miller,Fang Wang,Hua Yang,Yue Chen,Andrew Kernytsky,Marc K. Rosenblum,Wei Liu,Scott A. Biller,Shinsan M. Su,Cameron Brennan,Timothy A. Chan,Thomas G. Graeber,Katharine E. Yen,Ingo K. Mellinghoff,Ingo K. Mellinghoff +28 more
TL;DR: The recent discovery of mutations in metabolic enzymes has rekindled interest in harnessing the altered metabolism of cancer cells for cancer therapy, and isocitrate dehydrogenase 1 (IDH1), which is mutated in multiple human cancers, is examined.
1.1K
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid
Alexandra Miller,Ronak Shah,Elena Pentsova,Maryam Pourmaleki,Samuel Briggs,Natalie DiStefano,Youyun Zheng,Anna Skakodub,Smrutiben A. Mehta,Carl Campos,Wan-Ying Hsieh,S. Duygu Selcuklu,Lilan Ling,Fanli Meng,Xiaohong Jing,Aliaksandra Samoila,Tejus Bale,Dana W.Y. Tsui,Christian Grommes,Agnes Viale,Mark M. Souweidane,Mark M. Souweidane,Viviane Tabar,Cameron Brennan,Anne S. Reiner,Marc K. Rosenblum,Katherine S. Panageas,Lisa M. DeAngelis,Robert J. Young,Michael F. Berger,Ingo K. Mellinghoff,Ingo K. Mellinghoff +31 more
TL;DR: It is shown that tumour-derived DNA was detected in CSF from 42 out of 85 patients (49.4%) and was associated with disease burden and adverse outcome and the ability to monitor the evolution of the glioma genome through a minimally invasive technique could advance the clinical development and use of genotype-directed therapies for gliomas.
Genomic correlates of disease progression and treatment response in prospectively characterized gliomas
Philip Jonsson,Andrew L. Lin,Robert J. Young,Natalie DiStefano,David M. Hyman,Bob T. Li,Michael F. Berger,Ahmet Zehir,Marc Ladanyi,David B. Solit,Angela G. Arnold,Zsofia K. Stadler,Diana Mandelker,Michael E. Goldberg,Juliann Chmielecki,Maryam Pourmaleki,Shahiba Ogilvie,Shweta S. Chavan,Andrew T. McKeown,Malbora Manne,Allison Hyde,Kathryn Beal,T. Jonathan Yang,Craig Nolan,Elena Pentsova,Antonio Omuro,Igor T. Gavrilovic,Thomas Kaley,Eli L. Diamond,Jacqueline B. Stone,Christian Grommes,Adrienne Boire,Mariza Daras,Anna F. Piotrowski,Alexandra Miller,Philip H. Gutin,Timothy A. Chan,Viviane Tabar,Cameron Brennan,Marc K. Rosenblum,Lisa M. DeAngelis,Ingo K. Mellinghoff,Barry S. Taylor +42 more
TL;DR: These data reveal genomic correlates of disease progression and treatment response in diverse types of glioma and highlight the potential utility of incorporating genomic information into the clinical decision-making for patients with gliomas.
Leptomeningeal metastases in glioma: The Memorial Sloan Kettering Cancer Center experience
TL;DR: It was found that treatment of LMD was associated with superior performance status and increased survival and patients with LMD diagnosed at relapse may not have decreased overall survival as compared to historical controls with parenchymal relapse.
60
Next-generation Sequencing of Cerebrospinal Fluid for Clinical Molecular Diagnostics in Pediatric, Adolescent and Young Adult (AYA) Brain Tumor Patients.
Alexandra Miller,Luca Szalontay,Nancy Bouvier,K. Hill,Hamza Ahmad,Johnathan Rafailov,Alex J Lee,M I Rodriguez-Sanchez,Onur Yildirim,Arti Patel,Tejus Bale,Jamal Benhamida,Ryma Benayed,Maria E. Arcila,Maria Donzelli,Ira J. Dunkel,Stephen Gilheeney,Yasmin Khakoo,Kim Kramer,Sameer Farouk Sait,Jeffrey P. Greenfield,Mark M. Souweidane,Sofia Haque,Audrey Mauguen,Michael F. Berger,Ingo K. Mellinghoff,Matthias A. Karajannis +26 more
TL;DR: Three general categories where CSF cfDNA testing provided additional relevant diagnostic, prognostic, and/or therapeutic information, impacting clinical assessment and decision making are identified: 1) diagnosis and/ or identification of actionable alterations; 2) monitor response to therapy; and 3) tracking tumor evolution.
55